Alaska APRN Bundle

Course Overview

Course Authors

1. Edith Fomuso MSN, CCM, RN
2. Cathleen Adams CNO, RN CENP
3. Maureen Sullivan-Tevault MS, BSN, RN, CEN, CDE
4. Sarah Schulze MSN, NP
5. Amanda Marten MSN, FNP-C
6. Sadia A. MPH, MSN, WHNP-BC

Course Outline

1. Controlled Substances: A comprehensive review
2. Semaglutide and Type 2 Diabetes
3. Medication Assisted Treatment
4. Hypertensive Agents
5. Migraine Management
6. Asthma Treatment and Monitoring

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss APRN courses pertinent to renewal in Alaska. It will take the average learner 900 minutes to complete and awards 15 contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

1. Describe commonly prescribed opioids for pain management and understand their side effects and indications of use.
2. Describe the action of non-insulin injectable diabetes medication semaglutide.
3. Discuss the prevalence of various substance-related problems among United States citizens.  
4. Differentiate between the classes of antihypertensives and their mechanism of action. 
5. Demonstrate understanding of the neurobiological and pathophysiological mechanisms underlying migraines.  
6. Describe common side effects, including severe possible side effects, of medications used to manage asthma

Target Audience

• Registered Nurses (RN)
• Advanced Practice Registered Nurses (APRN)

Requirement for Completion

1. Enrollment in the course by the learner
2. Read and learn all course materials
3. Complete the course evaluation
4. Attest and testify learning of the course materials

Accreditations + Approvals

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.